{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NBTX",
  "name": "Nanobiotix S.A.",
  "url": "https://frontierpicks.com/dossiers/NBTX/",
  "json_url": "https://frontierpicks.com/dossiers/NBTX.json",
  "status": "WATCHLIST",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Nanobiotix shares are more likely to lag the S&P 500 over the next three months because the Phase 3 NANORAY-312 head and neck cancer readout that decides the case has no date. Cash runs into 2029, so news on that trial's timing or result is what settles the call.",
  "invalidation_trigger": "A daily close above $38.17, the 2026-08-13 close, which would erase the three-month decline and show the shares leading; or an announcement that the NANORAY-312 final analysis met its primary endpoint.",
  "catalyst_date": "2026-11-16",
  "portfolio": null,
  "pick": null,
  "themes": [
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Nanobiotix is a French company: ordinary shares trade on Euronext Paris (NANO) and American Depositary Shares on Nasdaq (NBTX).",
    "As a foreign private issuer, Nanobiotix files 6-K and 20-F reports, publishes half-year financials rather than quarterly ones, and its insiders do not file SEC Form 4.",
    "The lead asset, JNJ-1900 (NBTXR3), is licensed to Johnson & Johnson's Janssen unit, which runs the Phase 3 NANORAY-312 trial and controls its timing."
  ],
  "source_links": [
    {
      "title": "NANOBIOTIX Provides First Half 2026 Operational and Financial Update",
      "url": "https://mfn.se/all/a/nanobiotix/nanobiotix-provides-first-half-2026-operational-and-financial-update-8e2b4a94",
      "date": "2026-09-24"
    },
    {
      "title": "NANOBIOTIX Announces Closing of Global Offering",
      "url": "https://www.biospace.com/press-releases/nanobiotix-announces-closing-of-global-offering",
      "date": "2026-05-26"
    },
    {
      "title": "Nanobiotix S.A. - Form 6-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001760854/000117184326007272/exh_991.htm",
      "date": null
    },
    {
      "title": "Nanobiotix S.A. - Form 6-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001760854/000117184326006335/exh_991.htm",
      "date": "2026-10-01"
    }
  ],
  "evidence": [
    {
      "claim": "Cash and cash equivalents were €110.9 million at 2026-06-30, up from €52.8 million at 2025-12-31; the company says this funds operations into 2029.",
      "source": "Nanobiotix first-half 2026 operational and financial update, 2026-09-24",
      "as_of": "2026-06-30"
    },
    {
      "claim": "First-half 2026 net loss was €34.3 million versus €5.4 million in first-half 2025; revenue and other income was €5.6 million versus €26.6 million.",
      "source": "Nanobiotix first-half 2026 operational and financial update, 2026-09-24",
      "as_of": "2026-06-30"
    },
    {
      "claim": "Global offering closed with about $100 million (about €86.1 million) gross proceeds at €33.60 per ordinary share and $38.98 per ADS, a 14.92% discount to the prior three-session average.",
      "source": "Nanobiotix closing release, 2026-05-26",
      "as_of": "2026-05-26"
    },
    {
      "claim": "NANORAY-312 protocol amendment removed the planned interim analysis and set a final analysis on fewer events, with timing dependent on reaching the event count.",
      "source": "Nanobiotix first-half 2026 operational and financial update, 2026-09-24",
      "as_of": "2026-09-24"
    },
    {
      "claim": "Final Phase 1 Study 1100 data in anti-PD-1-resistant melanoma: 41.7% response rate, 4 complete responses, 75% disease control rate, 17.8-month median overall survival.",
      "source": "Nanobiotix release at ESMO, 2026-10-24",
      "as_of": "2026-10-24"
    },
    {
      "claim": "Arnd Christ appointed chief financial officer and executive board member effective 2026-10-01, succeeding Bart Van Rhijn.",
      "source": "Nanobiotix Form 6-K, 2026-10-01",
      "as_of": "2026-10-01"
    }
  ],
  "view_changes": [],
  "body_markdown": "## Current Thesis\nNanobiotix shares are more likely to lag the S&P 500 over the next three months than to lead it. The trial that decides the company's value, the Phase 3 NANORAY-312 study of JNJ-1900 (NBTXR3) in head and neck cancer, has no announced readout date. The two November investor conferences and any word on NANORAY-312 timing are what could change that.\n\nThe balance sheet is not the problem. Cash stood at €110.9 million on 2026-06-30, and the company's first-half update of 2026-09-24 says that funds operations into 2029. The problem is time. A protocol amendment dropped the planned interim analysis in favour of a final analysis on fewer events. The company says the final analysis should come in a similar timeframe to the old interim, but that timing depends on when the event count is reached. Without a dated readout, the shares have no scheduled catalyst inside the next 63 trading sessions.\n\nWhat the price already reflects: the shares closed at $32.95 on 2026-11-11. That is below the $38.98 per American Depositary Share (ADS) price of the global offering that closed on 2026-05-26 and 42.3% below the intraday 52-week high of $57.14 on 2026-05-14. The market has taken back most of the spring run while it waits for the Phase 3 result.\n\n## Bull Case\n- **Cash runs into 2029.** Cash was €110.9 million on 2026-06-30, up from €52.8 million on 2025-12-31, after the global offering of about $100 million gross that closed on 2026-05-26 (company releases of 2026-05-26 and 2026-09-24).\n- **Partner funds the pivotal trial.** Johnson & Johnson's Janssen unit runs NANORAY-312 under a 2023 licence, and Nanobiotix's first-half 2026 research and development spending fell to €12.7 million from €14.5 million a year earlier (first-half update, 2026-09-24).\n- **Melanoma data added a second indication.** Final Phase 1 data from Study 1100, presented at the European Society for Medical Oncology (ESMO) congress on 2026-10-24, showed a 41.7% response rate, 4 complete responses, a 75% disease control rate and 17.8-month median overall survival in anti-PD-1-resistant melanoma (company release, 2026-10-24).\n- **A faster path to the final analysis.** The NANORAY-312 amendment removed the interim analysis and cut the number of events needed for the final analysis, so the final read should come sooner than under the original design (first-half update, 2026-09-24).\n\n## Bear Case\n- **No dated readout for NANORAY-312.** The 2026-09-24 update gives no year or half for the final analysis and ties it to an event count that Janssen's trial must reach.\n- **Shares trade below the offering price.** The 2026-11-11 close of $32.95 sits under the $38.98 per-ADS price that institutions paid in May 2026, a price already set at a 14.92% discount to the prior three-session average (closing release, 2026-05-26).\n- **Losses widened sharply.** The first-half 2026 net loss was €34.3 million against €5.4 million a year earlier, and revenue and other income fell to €5.6 million from €26.6 million, which had included a one-off €21.2 million non-cash item (first-half update, 2026-09-24).\n- **Melanoma data is early.** The ESMO results come from a single-arm Phase 1 study; they do not substitute for a randomised Phase 3 outcome.\n- **Finance leadership changed.** Arnd Christ became chief financial officer on 2026-10-01, succeeding Bart Van Rhijn after five years (company 6-K, 2026-10-01).\n\n## Setup & Price Structure\nAdjusted daily closes put the shares at $32.95 on 2026-11-11. That is above the 50-day moving average of $30.71 and below the 200-day moving average of $34.22, both as of the same close. The 3-month change is -13.7%, measured against the $38.17 close of 2026-08-13.\n\nThe shares recovered from $29.70 on 2026-11-04 to $32.95 on 2026-11-11, closing higher in each of the last five sessions. The 200-day average at $34.22 is the first level above the price. The $38.17 close of 2026-08-13 and the $38.98 per-ADS offering price of May 2026 sit above that. The 52-week closing low is $19.97 on 2026-01-08; the 52-week intraday high is $57.14 on 2026-05-14.\n\n## Catalyst Calendar\n\n- **2026-11-16:** Chief executive Laurent Levy and finance chief Arnd Christ present at the Jefferies Global Healthcare Conference, London. The first management appearance since the ESMO melanoma data; any update on NANORAY-312 event accrual or final-analysis timing would bear directly on the call.\n- **2026-11-17:** Management participates in the UBS Global Biopharma Conference, London. A second venue for guidance on the Phase 3 readout window and on plans for the melanoma indication.\n- **~2027-03-31 (est.):** Full-year 2026 results and 20-F filing. Shows second-half 2026 cash burn against the runway into 2029 and may give the first dated window for the NANORAY-312 final analysis.\n\n## What Would Change Our Mind\n\nA daily close above $38.17, the 2026-08-13 close, which would erase the three-month decline and show the shares leading; or an announcement that the NANORAY-312 final analysis met its primary endpoint.\n\n## Correlation Notes\nNanobiotix trades mainly on its own clinical and partner news. Its main asset is licensed to Johnson & Johnson, so a statement from Janssen about NANORAY-312 matters more to the shares than sector moves. The ordinary shares also trade on Euronext Paris (ticker NANO), so Paris trading and the euro-dollar exchange rate feed into the US-listed ADS. Other Oncology & immunology names (Xencor, Genmab, Replimune) report on their own trial schedules; none shares a readout with Nanobiotix.",
  "first_seen": "2026-11-11",
  "last_analyzed": "2026-11-12T03:40:02+00:00",
  "last_synthesized": "2026-11-12",
  "date_modified": "2026-11-12",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}